Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy

PMID: 31827897
Journal: Future science OA (volume: 5, issue: 10, Future Sci OA 2019 Oct;5(10):FSO435)
Published: 2019-10-29

Kumar C, Bagga J, Chiliveru S, Kohli S, Bharadwaj A, Jain M, Inamdar S, Sharan B


Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma showing substantial remission post-administration of personalized dendritic cell-based vaccine APCEDEN in combination with chemotherapeutic drug Mitoxantrone. Therapeutic response displayed an interesting clinical correlation validated by PET scan images showing decreased fluorodeoxyglucose (FDG) avidity in the prostate gland, reduced skeletal metastases further established by the drop in serum Prostate Specific Antigen (PSA) levels and expression of immune assessment markers (IFN-γ, Tregs, neutrophil lymphocyte ratio and platelet lymphocyte ratio). This case demonstrates the potential efficacy of dendritic cell immunotherapy, showing a potent antitumor activity by enhancing the host immune responses, and improving quality of life.